Event Co-Sponsor
The KCSA Psychedelics Conference features live presentations and speakers who will address the various investment opportunities in psychedelic treatments for mental health disorders. The agenda highlights companies representing research, drug development, patient care delivery, integrated technology solutions, and patient support services that are crucial components of the reemerging psychedelic industry. Presenting companies include a variety of business models including drug developers, investment funds, care delivery treatment clinics, cGMP operators, and vertically integrated business models.
October 13th Agenda - Available for On-Demand Viewing
Small Pharma Inc.
TSX-V: DMT
Peter Rands, CEO
Dr Carol Routledge, Chief Scientific and Medical Officer
HMNC Brain Health
Private Company
Benedikt von Braunmühl, CEO
Maximilian Döbler, Head of Operations
Field Trip Health Ltd.
NASDAQ: FTRP | TSX: FTRP
Joseph del Moral, Co-Founder & CEO
Nathan Bryson, Chief Scientific Officer
FSD Pharma Inc.
NASDAQ: HUGE | CSE: HUGE
Anthony Durkacz, Founder, Interim CEO & Executive Co-Chairman of the Board
Dr. Lakshmi Kotra, CEO of Lucid
October 14th Agenda - Available for On-Demand Viewing
Mindset Pharma Inc.
OTCQB: MSSTF | CSE: MSET
James Lanthier, CEO
Joseph Araujo, Chief Scientific Officer
PsyBio Therapeutics Corp.
OTCQB: PSYBF | TSX-V: PSYB
Evan Levine, Co-Founder, CEO and Director
Bright Minds Biosciences Inc.
OTCQB: BMBIF | CSE: DRUG
Ian McDonald, President & CEO
Josh Blacher, VP of Corporation Development
Fireside Chat
Amy Emerson, CEO, MAPS Public Benefit Corp
Moderated by Tim Regan, SVP, KCSA Strategic Communications
Lunch Panel - Investing in Psychedelics and CNS Treatments
Lindsay Hoover, Partner, JLS Fund
Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments
Moderated by Tim Regan, SVP, KCSA Strategic Communications
.png){kind=logo}
